サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631148

免疫毒素の市場規模、シェア、動向分析レポート：製品別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年

Immunotoxins Market Size, Share & Trends Analysis Report By Product (Pseudomonas Exotoxin), By Application (Therapy Development), By End-use (Pharmaceutical & Biotechnology Companies), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
免疫毒素の市場規模、シェア、動向分析レポート：製品別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2024年12月11日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

免疫毒素市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の免疫毒素の市場規模は2030年までに2億4,330万米ドルに達し、2025年から2030年までのCAGRは8.23％を記録すると予測されています。

がんの有病率の上昇と技術の進歩は、市場成長を促進すると予想される要因の一部です。

免疫毒素は、細胞毒性薬剤と抗体や成長因子などの標的部分を組み合わせた標的治療薬の一種です。免疫毒素の開発は、さまざまながんやその他の疾患の治療に有効である可能性があることから、勢いを増しています。がんは世界的に関心が高まっており、2022年には新たに2,000万人が発症し、970万人が死亡すると推定されています。免疫毒素は、毒素に連結された抗体断片または標的部位から構成されており、毒性物質をがん細胞に直接選択的に送達することができます。さらに、免疫毒素の開発と応用は最近の動向の中で大きく発展しており、その有効性の向上、免疫原性の低減、治療応用の拡大を目指した様々な研究イニシアチブが進行中です。研究者たちは、新しい免疫毒素療法の標的となりうる新規の腫瘍特異的抗原を同定しつつあります。

COVID-19パンデミックは世界のサプライチェーンに大きな混乱をもたらしました。製造施設は保健規制や労働力不足による操業停止や操業縮小に直面しました。このような状況は、免疫毒素の製造に必要な原材料や成分の入手に影響を与えました。さらに、パンデミックは製薬会社、学術機関、政府機関の連携を促進し、医薬品開発プロセスを加速させ、市場の成長をさらに後押ししました。

しかし、免疫毒素療法に関連する主な課題のひとつは、重篤な副作用の可能性です。患者は吐き気、下痢、発熱などの副作用を経験する可能性があります。例えば、リシンベースの免疫毒素のような特定の毒素は、毛細血管漏出症候群や肝毒性のような重篤な合併症と関連しています。このようなリスクは、臨床試験の中止や医薬品承認プロセスにおける規制上の障害につながる可能性があり、市場の成長をさらに制限します。

免疫毒素市場レポートハイライト

  • 製品別では、ジフテリア毒素（DT）分野が2024年の市場シェア43.91%を占め、市場を独占しています。ジフテリア毒素は、がん細胞を攻撃するように設計された標的療法の一部として、がん治療に使用されています。
  • 用途別では、治療開発が市場の成長を牽引しており、予測期間中に8.29%の急成長が見込まれています。この成長の原動力となっているのは、研究開発投資の増加であり、特に、より精密で効果的な治療法を提供する標的がん治療への投資が増加しています。
  • 最終用途別では、製薬・バイオテクノロジー企業が2024年の市場シェア46.49%で免疫毒素市場を主要企業として牽引しています。これは主に、特定の病状に合わせた新しい免疫毒素を開発するための研究開発に多額の投資を行っているためです。
  • 地域別では、北米の免疫毒素市場が優位を占め、2024年には41.45％のシェアを占めました。この地域はヘルスケアのインフラが発達しており、大手バイオテクノロジー企業の存在感が強く、免疫学や腫瘍学の研究に多額の資金が投入されていることがその理由です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 免疫毒素市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し。
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 免疫毒素市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 免疫毒素市場：製品別の推定・動向分析

  • セグメントダッシュボード
  • 世界の免疫毒素市場：製品別の変動分析
  • 世界の免疫毒素市場規模と動向分析：製品別（2018年～2030年）
  • ジフテリア毒素（DT）
  • 炭疽菌由来の毒素
  • シュードモナス外毒素（PE）
  • その他の免疫毒素

第5章 免疫毒素市場：用途別の推定・動向分析

  • セグメントダッシュボード
  • 世界の免疫毒素市場：用途別の変動分析
  • 世界の免疫毒素市場規模と動向分析：用途別（2018年～2030年）
  • 生物医学研究
  • 治療法の開発

第6章 免疫毒素市場：最終用途別の推定・動向分析

  • セグメントダッシュボード
  • 世界の免疫毒素市場：最終用途別の変動分析
  • 世界の免疫毒素市場規模と動向分析：最終用途別（2018年～2030年）
  • 製薬・バイオテクノロジー企業
  • CROとCMO
  • 学術調査機関

第7章 免疫毒素市場：地域別の推定・動向分析

  • 地域別市場シェア分析（2024年・2030年）
  • 地域市場ダッシュボード
  • 市場規模と予測および動向分析（2018年～2030年）
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業/競合の分類
  • 戦略マッピング
  • 企業市況分析（2024年）
  • 企業プロファイル/上場企業
    • Creative Biolabs.
    • List Biological Labs, Inc.
    • The Native Antigen Company
    • Bio-Techne.
    • Abcam Plc.
    • CAYMAN CHEMICAL
    • Merck KGaA
    • Enzo Life Sciences, Inc.
    • Santa Cruz Biotechnology, Inc.
    • Quadratech Diagnostics Ltd.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global immunotoxins market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 17 Mexico immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 24 Germany immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 26 UK immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 27 UK immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 29 France immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 30 France immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 31 France immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 33 Italy immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 36 Spain immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 39 Denmark immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Sweden immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 42 Sweden immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Norway immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 45 Norway immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 51 China immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 52 China immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 53 China immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Japan immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 55 Japan immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 57 India immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 58 India immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 59 India immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 60 South Korea immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 61 South Korea immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 63 Australia immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 64 Australia immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 67 Thailand immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 71 Latin America immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 74 Brazil immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 77 Argentina immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 79 MEA immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 81 MEA immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 84 South Africa immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 90 UAE immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 93 Kuwait immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait immunotoxins market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Immunotoxins market: Market outlook
  • Fig. 5 Immunotoxins market: Segment outlook
  • Fig. 6 Immunotoxins market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Immunotoxins market driver impact
  • Fig. 9 Immunotoxins market restraint impact
  • Fig. 10 Immunotoxins market: Product outlook and key takeaways
  • Fig. 11 Immunotoxins market: Product movement analysis
  • Fig. 12 Diphtheria toxin (DT) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Anthrax based toxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Pseudomonas exotoxin (PE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Other immunotoxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Immunotoxins market: Application outlook and key takeaways
  • Fig. 17 Immunotoxins market: Application movement analysis
  • Fig. 18 Biomedical research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Therapy development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Immunotoxins market: End Use outlook and key takeaways
  • Fig. 21 Immunotoxins market: End Use movement analysis
  • Fig. 22 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 23 CROs & CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Global immunotoxins market: Regional outlook and key takeaways
  • Fig. 26 Global immunotoxins market: Regional movement analysis
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Key country dynamics
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Key country dynamics
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-464-4

Immunotoxins Market Growth & Trends:

The global immunotoxins market size is expected to reach USD 243.3 million by 2030, registering a CAGR of 8.23% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and technological advancements are some of the factors anticipated to drive market growth.

Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.

The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth.

However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.

Immunotoxins Market Report Highlights:

  • Based on product, Diphtheria Toxin (DT) segment dominated the product segment in the market with a market share of 43.91% in 2024. Diphtheria toxin has been used in cancer treatment as part of targeted therapies designed to attack cancer cells.
  • Based on application, Therapy development is driving the growth of the market and is expected to see the fastest growth rate of 8.29% during the forecast period. This growth is driven by increasing investment in R&D, particularly in targeted cancer therapies, which offer more precise and effective treatment options.
  • Based on end-use, Pharmaceutical and biotechnology companies are leading the immunotoxins market with a market share of 46.49% in 2024. This is mainly due to their significant investment in research and development to create new immunotoxins tailored for specific medical conditions.
  • Based on region, North America immunotoxins market dominated the market and accounted for 41.45% share in 2024, attributed to the region's advanced healthcare infrastructure, strong presence of leading biotechnology firms, and significant funding for immunology and oncology research.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Immunotoxins Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Cytotoxic and manufacturing challenges associated with immunotoxins
  • 3.3. Immunotoxins Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Immunotoxins Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Immunotoxins Market Product Movement Analysis
  • 4.3. Global Immunotoxins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Diphtheria Toxin (DT)
    • 4.4.1. Diphtheria toxin (DT) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Anthrax Based Toxins
    • 4.5.1. Anthrax based toxins market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Pseudomonas Exotoxin (PE)
    • 4.6.1. Pseudomonas exotoxin (PE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Immunotoxins
    • 4.7.1. Other immunotoxins market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunotoxins Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Immunotoxins Market Application Movement Analysis
  • 5.3. Global Immunotoxins Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Biomedical Research
    • 5.4.1. Biomedical research market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Therapy Development
    • 5.5.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunotoxins Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Immunotoxins Market End Use Movement Analysis
  • 6.3. Global Immunotoxins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. CROs & CMOs
    • 6.5.1. CROs & CMOs market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Academic & Research Institutes
    • 6.6.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunotoxins Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Competitive scenario
      • 7.4.1.3. Regulatory framework
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Creative Biolabs.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. List Biological Labs, Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. The Native Antigen Company
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bio-Techne.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Abcam Plc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. CAYMAN CHEMICAL
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Merck KGaA
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Enzo Life Sciences, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Santa Cruz Biotechnology, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Quadratech Diagnostics Ltd.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives